The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of semaglutide (Ozempic, Novo Nordisk) for the treatment of adults with type ...

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to ...